Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/04/23Free

Executive/Senior Manager

400,000 0.6684%
01/02/23Free

Chief Technology Officer

400,000 0.6686%
01/02/23Free

Chief Operating Officer

400,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 2.95M
+1.03%+2.30%+55.91%+115.16% 56.42B
+2.72%+3.26%+46.05%+47.37% 44.54B
+1.12%+2.79%-15.04%-18.40% 22.9B
+1.17%+3.85%-0.89%+407.26% 21.21B
-0.32%+1.97%+16.91%-34.50% 16.4B
+0.15%+2.24%+9.32%-39.25% 15.4B
-0.69%+0.82%+27.75%+182.91% 13.35B
+1.06%+9.84%+17.67% - 12.36B
+1.61%+1.28%+95.75%+206.59% 11.15B
Average -0.55%+2.09%+28.16%+108.39% 23.75B
Weighted average by Cap. +1.16%+2.37%+32.38%+101.31%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!